A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing MS when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population PK of BIIB033 when used concurrently with Avonex

Stanford is now accepting new patients for this trial. Please contact SPECTRUM at for more information.

Intervention(s):

  • drug : Interferon Beta-1a
  • drug : BIIB033 (anti-LINGO-1 mAb)
  • other : Placebo

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - 58 Years

Inclusion Criteria

- Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) or onset of Secondary Progressive Multiple Sclerosis (SPMS) - RRMS and SPMS subjects must have evidence of ongoing disease activity within 12 months of enrollment. - All male and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment Key

External Links

Contact information

Primary Contact:

SPECTRUM

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: